31 / 38
Page 81
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Biotechnol Biomater, an open access journal
ISSN: 2155-952X
Bio America 2017
October 19-20, 2017
October 19-20, 2017 | New York, USA
18
th
Biotechnology Congress
Molecular cloning involving AAV-CXCL 12 gene
Kripa Raj Ahuja
The University of North Carolina at Chapel Hill, USA
T
he American Cancer Society reports that this year there will be an estimated 600, 920 deaths due to cancer in the United States.
Current cancer research includes the use of biomarkers on the surface of cancer cells to distinguish the cancerous cells from
normal body cells. Molecular cloning can enhance these biomarkers. Over the past thirty years, molecular cloning has progressed
immensely. From digestion to plasmid insertion, the possibilities are endless. The AAV (Adeno Associated Virus) CXCL 12(C-X-C
Motif Chemokine Ligand 12) is a Protein Coding gene that shows great promise with cloning and plasmid insertion. Our project
aims to use this gene to bind tightly to biomarkers on the surface of cancer cells. However, before this optimal binding can occur, it is
essential to know more about the AAV CXCL 12 Gene itself. For this reason, our project includes multiple gel electrophoresis assays,
plasmid insertion/digestion assays, and PCR purification. From the results of these assays, the efficacy of AAV CXCL 12 to bind to
cancer biomarkers will become clear. In particular, the cloning assay for the AAV CXCL 12 gene holds great potential, as it is possible
to clone extraneous DNA into a different host. If extraneous DNA can be cloned into a different host, then there is the possibility of
that DNA binding to a biomarker on a cancer cell.
kripa@live.unc.eduJ Biotechnol Biomater 2017, 7:4 (Suppl)
DOI: 10.4172/2155-952X-C1-080